Emtricitabine; Rilpivirine Hydrochloride; Tenofovir Disoproxil Fumarate Patent Expiration
Emtricitabine; Rilpivirine Hydrochloride; Tenofovir Disoproxil Fumarate is Used for managing and treating HIV infection. It was first introduced by Gilead Sciences Inc
Emtricitabine; Rilpivirine Hydrochloride; Tenofovir Disoproxil Fumarate Patents
Given below is the list of patents protecting Emtricitabine; Rilpivirine Hydrochloride; Tenofovir Disoproxil Fumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Complera | US10857102 | Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate | Jan 14, 2033 | Gilead Sciences Inc |
| Complera | US8841310 | Combinations of a pyrimidine containing NNRTI with RT inhibitors | Dec 09, 2025 | Gilead Sciences Inc |
| Complera | US7125879 | HIV inhibiting pyrimidines derivatives |
Apr 21, 2025
(Expired) | Gilead Sciences Inc |
| Complera |
US8716264 (Pediatric) | Compositions and methods for combination antiviral therapy |
Jul 13, 2024
(Expired) | Gilead Sciences Inc |
| Complera | US8592397 | Compositions and methods for combination antiviral therapy |
Jan 13, 2024
(Expired) | Gilead Sciences Inc |
| Complera | US8716264 | Compositions and methods for combination antiviral therapy |
Jan 13, 2024
(Expired) | Gilead Sciences Inc |
| Complera | US9457036 | Compositions and methods for combination antiviral therapy |
Jan 13, 2024
(Expired) | Gilead Sciences Inc |
| Complera | US9744181 | Compositions and methods for combination antiviral therapy |
Jan 13, 2024
(Expired) | Gilead Sciences Inc |
| Complera | US8080551 | HIV inhibiting pyrimidines derivatives |
Apr 11, 2023
(Expired) | Gilead Sciences Inc |
| Complera | US8101629 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Aug 09, 2022
(Expired) | Gilead Sciences Inc |
| Complera |
US6703396 (Pediatric) | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep 09, 2021
(Expired) | Gilead Sciences Inc |
| Complera |
US6642245 (Pediatric) | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May 04, 2021
(Expired) | Gilead Sciences Inc |
| Complera | US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar 09, 2021
(Expired) | Gilead Sciences Inc |
| Complera | US6838464 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
Feb 26, 2021
(Expired) | Gilead Sciences Inc |
| Complera | US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov 04, 2020
(Expired) | Gilead Sciences Inc |
| Complera | US7067522 | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
Dec 20, 2019
(Expired) | Gilead Sciences Inc |
| Complera |
US5922695 (Pediatric) | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan 25, 2018
(Expired) | Gilead Sciences Inc |
| Complera |
US5935946 (Pediatric) | Nucleotide analog composition and synthesis method |
Jan 25, 2018
(Expired) | Gilead Sciences Inc |
| Complera |
US5977089 (Pediatric) | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan 25, 2018
(Expired) | Gilead Sciences Inc |
| Complera |
US6043230 (Pediatric) | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan 25, 2018
(Expired) | Gilead Sciences Inc |
| Complera |
US5914331 (Pediatric) | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan 02, 2018
(Expired) | Gilead Sciences Inc |
| Complera | US5922695 | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul 25, 2017
(Expired) | Gilead Sciences Inc |
| Complera | US5935946 | Nucleotide analog composition and synthesis method |
Jul 25, 2017
(Expired) | Gilead Sciences Inc |
| Complera | US5977089 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul 25, 2017
(Expired) | Gilead Sciences Inc |
| Complera | US6043230 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul 25, 2017
(Expired) | Gilead Sciences Inc |
| Complera | US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul 02, 2017
(Expired) | Gilead Sciences Inc |
| Complera |
US5814639 (Pediatric) | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar 29, 2016
(Expired) | Gilead Sciences Inc |
| Complera | US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep 29, 2015
(Expired) | Gilead Sciences Inc |
Emtricitabine; Rilpivirine Hydrochloride; Tenofovir Disoproxil Fumarate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List